article · Open Forum Infectious Diseases

Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda

Jillian L. Kadota
Achilles Katamba
Patrick Phillips
Jane Nakimuli
David W. Dowdy
Fred Welishe
Christopher A. Berger
Adithya Cattamanchi
Hélène E. Aschmann
Noah Kiwanuka
Allan Musinguzi
Lydia Akello
Fred C. Semitala

20243 citationsOpen accessMakerere University

Abstract

In a routine setting, 3HP was safe, with 16% of people with HIV reporting AEs and only 3% requiring temporary or permanent treatment interruption. These findings support 3HP expansion in routine HIV/AIDS care settings for TB prevention. <b>Clinical Trials Registration.</b> NCT03934931.

Research topics

Tuberculosis Research and Epidemiology
Pneumocystis jirovecii pneumonia detection and treatment
HIV/AIDS Research and Interventions

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1093/ofid/ofae667

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.